Heparin pharmacokinetics and pharmacodynamics

Area of Science:

• Pharmacology
• Biochemistry
• Hematology

Background:

• Heparin, an endogenous glycosaminoglycan, has been a cornerstone in treating thromboembolic disorders for 50 years.
• Available as unfractionated heparin (UFH) and low molecular weight heparin (LMWH), differing in molecular weight and composition.
• Heparin exerts its antithrombotic effect by forming a complex with antithrombin III, which then inhibits thrombin.

Purpose of the Study:

• To review the properties, mechanisms of action, and disposition of heparin and low molecular weight heparin.
• To highlight the differences in elimination pathways between UFH and LMWH.
• To address the ongoing need for better correlation between laboratory tests and clinical antithrombotic effects.

Main Methods:

• Literature review of heparin's discovery, properties, and clinical use.
• Analysis of heparin's pharmacokinetic profile, including distribution and elimination.
• Comparison of UFH and LMWH regarding molecular weight, elimination, and antithrombotic mechanisms.

Main Results:

• Heparin's antithrombotic activity relies on a specific pentasaccharide sequence for antithrombin III binding.
• UFH exhibits a complex elimination curve due to saturable and nonsaturable (renal) mechanisms.
• LMWH primarily uses renal elimination, lacking the characteristic concave-convex disposition curve of UFH.

Conclusions:

• Both UFH and LMWH are effective antithrombotic agents.
• Renal elimination is the primary route for LMWH.
• Further research is needed to clarify the relationship between in vitro laboratory tests and the actual antithrombotic efficacy of heparin preparations.